News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
PharmaMar S.A. Release: FDA Grants IND For FDA’s ZALYPSISÒ To Enter Phase I Clinical Trials In US
January 31, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PharmaMar announced today that its Investigational New Drug application (IND) has been accepted by the US Food and Drug Administration (FDA) for the clinical testing of Zalypsis® (PM00104/50), PharmaMar's novel marine anti-tumour agent.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 1
Europe
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Infectious disease
GSK, Ionis’ hepatitis B functional cure effectively eliminates virus in nearly 20% of patients
May 28, 2026
·
2 min read
·
Tristan Manalac
Insights
France’s biotech ecosystem: science, capital and scale
May 28, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Rare diseases
FDA accepts BridgeBio’s application for potential first limb-girdle muscular dystrophy drug
May 27, 2026
·
3 min read
·
Heather McKenzie
Immunology and inflammation
Apogee investors riled by $1.3B royalty deal, as eczema drug matches Lilly’s Ebglyss
May 27, 2026
·
3 min read
·
Annalee Armstrong
